Y
Youjin Je
Researcher at Kyung Hee University
Publications - 75
Citations - 4388
Youjin Je is an academic researcher from Kyung Hee University. The author has contributed to research in topics: Prospective cohort study & Relative risk. The author has an hindex of 30, co-authored 69 publications receiving 3658 citations. Previous affiliations of Youjin Je include Harvard University & Yonsei University.
Papers
More filters
Journal ArticleDOI
Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer: A Meta-analysis of Randomized Trials
Paul L. Nguyen,Youjin Je,Fabio A.B. Schutz,Karen E. Hoffman,Jim C. Hu,Arti Parekh,Joshua A. Beckman,Toni K. Choueiri +7 more
TL;DR: A systematic review and meta-analysis of randomized trials to determine whether androgen deprivation therapy (ADT) is associated with cardiovascular mortality, prostate cancer-specific mortality (PCSM), and all-cause mortality in men with unfavorable-risk, nonmetastatic prostate cancer was performed in this article.
Journal ArticleDOI
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
TL;DR: Treatment with VEGFR TKIs sunitinib and sorafenib is associated with a significant increase in the risk of ATEs, and random-effects or fixed-effects models based on the heterogeneity of included studies were used.
Journal ArticleDOI
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
Guillermo de Velasco,Youjin Je,Dominick Bossé,Mark M. Awad,Patrick A. Ott,Raphael Brandao Moreira,Fabio A.B. Schutz,Joaquim Bellmunt,Guru Sonpavde,F. Stephen Hodi,Toni K. Choueiri +10 more
TL;DR: There is substantial evidence that ICIs are associated with a small but significant increase in risk of selected all-grade irAEs and high-grade gastrointestinal and liver toxicities, and AEs should be recognized promptly as early interventions may alleviate future complications.
Journal ArticleDOI
Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
Toni K. Choueiri,Erica L. Mayer,Youjin Je,Jonathan E. Rosenberg,Paul L. Nguyen,Georges Azzi,Joaquim Bellmunt,Harold J. Burstein,Fabio A.B. Schutz +8 more
TL;DR: This is the first comprehensive report to show that bevacizumab is associated with an increased risk of significant heart failure in patients with breast cancer.
Journal ArticleDOI
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
TL;DR: Treatment with the VEGFR tyrosine-kinase inhibitors sunitinib and sorafenib is associated with a significant increase in risk of bleeding.